Article

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial

2014-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5f8d5925-3ba7-5ed6-9aef-cb7f74628d7f
DOI: 10.1186/2051-1426-2-s3-p12
PMCID: PMC4288417

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialDOI 10.1186/2051-1426-2-s3-p12Read

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read

Fully human CD19-specific chimeric antigen receptors for T-cell therapySemantic proximity Read

CAR therapy: the CD19 paradigmSemantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read

Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapySemantic proximity Read

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read

CAR-T Cell TherapySemantic proximity Read

First-Ever CAR T-cell Therapy Approved in U.S.Semantic proximity Read

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read